Astec Lifescience Ltd - Research Report

 
To get a call back from your Relationship Manager, just give a missed call at +91-9773076000

Private Client Research

Rating

Buy

Sector

Chemicals

Company

Astec Lifescience Ltd

Reco Price
Rs. 61.7
Price Target (12 Months)
Rs. 125
Upside
102.59%

Date

30 July 2014
Sensex
26087.42
CNX Nifty
7791.4

Exchange

Code

NSE
ASTEC
BSE
533138

Backward integration will lead to improvement in margins.

Strong Reputation:
Astec manufactures a wide range of Agrochemical active ingredients and pharmaceutical intermediates. Astec's considerable experience in the development and production of intermediates and active ingredients makes it an ideal partner. Astec has forged enduring relationships with large and small companies all over the world. Astec has an unshakeable reputation for providing quality products in manufacturing plants that meet global standards.

Rich Experience:
Astec Lifescience has rich experience of over two decades in the chemical industry. They employ highly qualified and trained individuals to monitor and maintain its manufacturing activities as well as process development work. The company prides itself in being responsive, reliable and quick to implement projects. At the same time they ensure high levels of confidentiality in implementing new projects thereby providing an excellent customized manufacturing service option to their clients at extremely competitive costs.

Successful Model:
Company does business through contract manufacturing which is success model and also company's plants are complied with EHS standard which makes its plant with world class facility.Also Company has done big contracts in last one year where they have tied up with Sumitomo which is a Japanese player. Sumitomo is a $20 Billion company.

Strong Sales:
Out of the total sales, Agro chemicals contribute majority part while pharma segment contributes rest. Currently the exports of the company are 40% of the total sales. It has huge domestic and international clientele with long term contracts. Domestic clients include Syngenta India, Indofil chemicals, Atul Ltd, Krishi rasayan exports and international clientele includes Irvita Plant Protection, Nufarm UK ltd, An Nong Co, handelsgesellschaft, Detlef Von Appen, Sumitomo, etc. Also to boost Sales Company has started retail business through its subsidiary by Excel crop care products (100% subsidiary) which include Insecticides, Herbicides and fungicides. This shows the clear intent of the company where they are trying to diversify the portfolio to improve on their sales performance.

Catalogue products:
This segment is called Triazole fungicide segment and in that the names of the product Tebuconazole or Propiconazole, Difenoconazole, Hexaconazole they are all Triazole fungicide segment of the industry in the fungicidal segment which is specialized in niche area where company operates where they have a core competence because of backward integrations, lateral integrations. Hence due backward integration company is able to save a lot in terms of expenses.

Expanded Operations:
Company operated in three states that is Karnataka, Gujarat, and Maharashtra. They have already rolled out in Punjab, Haryana and Madhya Pradesh but to give you a flavor, the market is growing at the rate of 15% per year. Today the market size is $2 billion market which is expected to be by 2020. Company strategies specifically are to succeed in this market and then forward integration of co-products which they manufacture. Hence company is continuously expanding its operations geographically to improve on its margins.

Stock Data

CMP (Rs)
63
Face value (Rs)
10
52 Week Range (Rs)
63 -16
Market cap (Rs Crores)
115.80
Price To Book Value (x)
1.02
P/E Ratio (x)
12.63
EV/EBIDTA (x)
5.06

One Year indexed Stock Performance

Astec Lifescience LtdSensex
Astec Lifescience Ltd
Performance (%)
1m
6m
12m
Absolute
27.74
87.82
270.57
Sensex
2.65
23.52
35.05

Shareholders

(in %)
31-Mar
Promoter
58.05
FII
0
DII
0
Others
41.95
Total
100

+91 22 6639 3000
research@stockaxis.com

 

Industry

The Agro-chemicals Industry grows in tandem with the agricultural sector. Agricultural growth itself is greatly affected by monsoon, especially in the agrarian economies with large tracts of land-mass remaining uncovered with water irrigation systems. Thus, a year of good monsoon is a harbinger of growth for the agrarian economies, including Agro-chemicals Industry. Conversely, the vagaries of monsoon tend to be a spoiler for the sector. As is well known, countries with large and growing population are forever under pressure for higher food produce from their limited land mass; the arable land itself is limited and getting shrunk all over the world in the wake of industrial development and urbanization. The scenario makes it imperative for the stakeholders in the agriculture space to look for and adopt new and more efficient methods of crop protection and of maximizing their yields from the given land resources under cultivation. Agro-chemicals are gaining acceptance worldwide with increasing awareness of their beneficial role in minimizing losses due to pests and thereby improving yields. For the players in the Agro-chemicals Industry, the challenge is to develop new products through research and innovation for more efficient crop protection through safe and efficient products and product applications across broad spectrum of agricultural crops in all parts of the world.

Profile

ASTEC Life Science Ltd is engaged in the manufacture & sale of intermediates, active ingredients and formulations in the off patent–proprietary category with a focus on agrochemical and pharmaceutical industry. Astec Life Science Ltd has three manufacturing units located in Maharashtra i.e. one unit at Dombivli & two units at Mahad with one of the unit being an EoU. Company exports its products to East Asia, Europe, Middle East and USA. Hexaconazole, Tebuconazole, Metalaxyl and Propiconazole are some of the key products in agrochemical segment which contributes its majority of sales.

Profit & Loss Statement:- (Consolidated)
(Rs Crores)
Particulars
Mar-11
Mar-12
Mar-13
Mar-14
Mar-15E
Mar-16E
Income:-
  • Net Sales
  • Growth (%)
  • Total Expenditure
  • EBITDA
  • EBITDA margin (%)
  • Other Income
  • Operating Profit
  • Interest
  • PBDT
  • Depreciation
  • Profit Before Taxation
    & Exceptional Items
  • Provision for Tax
  • Profit After Tax
  • PAT Margin (%)
  • Adjusted EPS
  • 109.44
  • -
  • 93.80
  • 15.64
  • 14.29
  • 1.21
  • 16.85
  • 4.06
  • 12.79
  • 5.83
  • 6.96
  •  
  • 2.09
  • 4.88
  • 4.46
  • 2.88
  • 112.84
  • 3.11
  • 97.35
  • 15.50
  • 13.73
  • 0.61
  • 16.11
  • 5.66
  • 10.45
  • 8.64
  • 1.81
  •  
  • 0.54
  • 1.27
  • 1.13
  • 0.81
  • 174.77
  • 54.88
  • 147.77
  • 27.01
  • 15.45
  • 1.06
  • 28.07
  • 7.48
  • 20.58
  • 11.87
  • 8.71
  •  
  • 2.81
  • 5.90
  • 3.38
  • 3.30
  • 206.97
  • 18.42
  • 171.60
  • 35.37
  • 17.09
  • 0.00
  • 35.37
  • 9.25
  • 26.12
  • 14.77
  • 11.35
  •  
  • 2.50
  • 8.85
  • 4.28
  • 4.99
  • 258.85
  • 25.07
  • 211.50
  • 47.35
  • 18.29
  • 0.45
  • 47.80
  • 10.50
  • 37.30
  • 16.50
  • 20.80
  •  
  • 6.24
  • 14.56
  • 5.62
  • 8.21
  • 325.00
  • 25.56
  • 263.5
  • 61.50
  • 18.92
  • 0.41
  • 61.91
  • 11.75
  • 50.16
  • 18.25
  • 31.91
  •  
  • 9.573
  • 22.34
  • 6.87
  • 12.59
Source: Stockaxis Research, Company Data

Valuation

Considering the large capex done and rich experience of over two decades in the chemical industry Astec life science is becoming a very strong player in the market. Company has already entered into retail segment with its own brand which will help them to improve the composition of sales .Also company is trading at very reasonable valuation, At CMP 61.70 of Rs stock is trading at 4.90x FY2016E which is a very reasonable valuation considering its growth prospects in next two years.

We assign valuation of 9.92 x to FY2016E indicating target price of Rs 125 which is a fair valuation of stock considering the strong financial metrics. our time horizon is more than one year.

 

Disclaimer

This report is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person.

This material is for the personal information of the authorized recipient, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of the users of stockaxis.com. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual users.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and we do not warrant its accuracy or completeness.

Neither stockaxis.com, nor any person connected with it, accepts any liability arising from the use of this document. The recipients of this material should rely on their own investigations and take their own professional advice. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions -including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis based on studying charts of a stock’s price movement and trading volume, as opposed to focusing on a company’s fundamentals and as such, may not match with a report on a company’s fundamentals. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our users that reflect opinions that are contrary to the opinions expressed herein.

Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavour to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

We and our affiliates, officers, directors, and employees may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn fees or other compensation or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential conflict of interest with respect to any recommendation and related information and opinions.

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.